Kluizen Pharma SRL
Kluizen Pharma reported total assets of €1.74m at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Jan 2026).
The score of Kluizen Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +61 % Total assets +54 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Kluizen Pharma's annual accounts
Filed annual accounts
- Year ended 30 Jun 2025filed on 30 Jan 2026
- Year ended 30 Jun 2024filed on 04 Feb 2025
- Year ended 30 Jun 2023filed on 30 Jan 2024
- Year ended 30 Jun 2022filed on 09 Jan 2023
- Year ended 30 Jun 2021filed on 24 Dec 2021
Kluizen Pharma's financial analysis
- Solvency38.1%sector median: 55.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Kluizen Pharma
Kluizen Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0501.612.041
- VAT number
- BE0501612041
- Peppol
- Registered · 0208:0501612041 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 20 Nov 2012
- Registered office
- 9940 Evergem
- Latest accounts
- 2025 · filed on 30 Jan 2026
- Activity
- Activities of holding companies (NACE 64210)
Kluizen Pharma (SRL) has been based in Evergem since 2012, active in: activities of holding companies. For 2025, it reports a net profit of 112,591 € and equity of 663,862 €; its revenue is not published. Its solvency stands at 38.1%, below the median of its sector (55.6%).
Companies similar to Kluizen Pharma
Companies in the same business, of comparable size and area, outside its group.
- RMB Immo Activities of holding companies Herve · balance sheet €1.93m
- Gradatus Activities of holding companies Nazareth-De Pinte · balance sheet €1.94m
- Borvan Activities of holding companies Dentergem · balance sheet €1.53m
- Huysmans Invest Activities of holding companies Forest · balance sheet 254,978 €
- HGS Investments Activities of holding companies Lokeren · balance sheet €1.82m
- DE KOE Activities of holding companies Grobbendonk · balance sheet €2.04m
- Helianco Activities of holding companies Bilzen-Hoeselt · balance sheet €1.48m
- Wesor Activities of holding companies Bertem · balance sheet €2.35m
Frequently asked questions about Kluizen Pharma
What is the revenue of Kluizen Pharma?
Kluizen Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Kluizen Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0501612041 for Kluizen Pharma, if the company is VAT-registered. Its company number (CBE) is 0501.612.041.
Where is the registered office of Kluizen Pharma?
According to the CBE register, the registered office of Kluizen Pharma is in 9940 Evergem.
What is the equity of Kluizen Pharma?
At the close of the 2025 financial year, the equity of Kluizen Pharma amounts to 663,862 €, a solvency of 38.1% of total assets.
Who manages Kluizen Pharma?
The register lists 2 active mandates at Kluizen Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Kluizen Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →